JPRN-UMIN000001617已完成1 期
A multicenter phase I/II study of irinotecan (CPT-11) and S-1 combination chemotherapy for metastatic colorectal cancer (CRC) - C-0401
CPT-11/TS-1 study group0 个研究点目标入组 30 人开始时间: 2009年1月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Serious drug hypersensitivity or a history of drug allergy 2. Plerral effusion, peritoneal fluid and pericardial fluid 3.Active infections 4. Water solubility diarrhea, in case of the patient who has a colostomy, diarrhea impairs daily life activity 5.Intestines tube paralysis, intestinal obstruction and peptic ulcer 6. interstitial pnumonitis, pulmonary fibrosis 7.Need to treatment with flucytosine 8.Active concomitant malignancy 9.diabetic that cannot be controlled 10. symptomatic or asymptomatic but treated heart disease 11. histry of mental disturbances or cerebrovascular attach 12. under coutinuous steroid therapy 13. Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers 14.Other conditions not suitable for this study
研究者
相似试验
已完成
2 期
A Randomized, phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small-cell lung cancer HOT1401/NJCLG1401JPRN-UMIN000013882orth Japan Lung Cancer Study Group and Hokkaido Lung Cancer Clinical Study Group80
已完成
2 期
Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal canceradvanced/metastatic colorectal cancerJPRN-UMIN000004882PO Hokkaido Gastrointestinal Cancer Study Group (HGCSG)80
已完成
2 期
Randomized phase II trial of irinotecan(CPT-11) plus tegafur/uracil with oral leucovorin(UFT/LV) compared with FOLFIRI in patients with unresectable/recurrent colorectal cancerPatients with previously untreated and unresectable/recurrent colorectal cancerJPRN-UMIN000000951Department of Surgery, School of Medicine, Keio University72
终止
2 期
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and OligodendrogliomasOligodendrogliomaGliomaAstrocytomaNCT00360828H. Lee Moffitt Cancer Center and Research Institute10
进行中（未招募）
不适用
Phase II study of irinotecan weekly in combination with trastuzumab in patientswith locally advanced or metastatic HER2-positive breast cancer and increased cancer cell copy number of TOP1”Metastatic breast cancerEUCTR2012-002347-23-DKDanish Breast Cancer Group (DBCG)